Company CARsgen Therapeutics Holdings Limited

Equities

2171

KYG1996C1006

Biotechnology & Medical Research

Analysts' Consensus

Business Summary

Managers

Members of the board

Share class

Shareholders

Company contact information

Sector

Sales per region

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Bio Therapeutic Drugs

Market Closed - Hong Kong S.E. Other stock markets 04:08:20 2024-04-26 am EDT			5-day change	1st Jan Change
5.45 ^HKD	+2.25%		+21.11%	-16.15%

Apr. 12	Carsgen Therapeutics To Give Cancer Drug Oral Presentation at ASCO 2024	MT
Mar. 26	CARsgen Therapeutics Holdings Limited Reports Earnings Results for the Full Year Ended December 31, 2023	CI

CARsgen Therapeutics Holdings Ltd is a China-based investment holding company principally engaged in discovering, developing and commercializing innovative chimeric antigen receptor (CAR)-T cell therapies. The Companyâs therapies are applied in the treatment of hematological malignancies and solid tumors. The Company have developed an upgraded B cell maturation antigen (BCMA) targeted CAR-T product, CT053, which is its sole core product candidate. The Company conducts its businesses in China and the United States.

Number of employees: 516

Managers	Title	Age	Since
Hua Mao Wang FOU	Founder	48	18-02-08
Zong Hai Li CEO	Chief Executive Officer	51	18-02-08
Lan Xie DFI	Director of Finance/CFO	52	21-02-28
Hong Ma CTO	Chief Tech/Sci/R&D Officer	54	18-07-31
Raffaele Baffa CTO	Chief Tech/Sci/R&D Officer	65	22-04-06
Hua Jiang BRD	Director/Board Member	45	21-03-31
Sylvie Peltier LAW	General Counsel	60	22-10-30
Guan Jun Zhou LAW	General Counsel	-	-
Wing Yat Lui SEC	Corporate Secretary	35	21-02-22
Leigh Hsu PRN	Corporate Officer/Principal	54	17-05-31

Members of the board	Title	Age	Since
Zong Hai Li CEO	Chief Executive Officer	51	18-02-08
Hua Mao Wang FOU	Founder	48	18-02-08
Xiang Ke Zhao BRD	Director/Board Member	38	23-07-03
Rong Gang Xie BRD	Director/Board Member	39	20-09-17
Bing Sen Guo BRD	Director/Board Member	54	18-09-12
Hua Qing Guo BRD	Director/Board Member	36	20-09-17
Guang Mei Yan BRD	Director/Board Member	67	21-06-17
Hua Jiang BRD	Director/Board Member	45	21-03-31
Hua Bing Li BRD	Director/Board Member	43	23-03-08

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	575,643,915	337,956,699 ( 58.71 %)	0	58.71 %

Name	Equities	%	Valuation
Zong Hai Li 37.45 %	215,572,730	37.45 %	166 M $
Aegon-Industrial Fund Management Co., Ltd. 3.992 %	22,981,000	3.992 %	18 M $
Loyal Valley Capital Co. Ltd. 3.860 %	22,222,244	3.860 %	17 M $
Shanghai Bioveda Investment Management Consulting Co. Ltd. 1.098 %	6,317,706	1.098 %	5 M $
Fullgoal Fund Management Co., Ltd. 1.058 %	6,087,500	1.058 %	5 M $
China Asset Management Co., Ltd. 0.6320 %	3,638,000	0.6320 %	3 M $
GF Fund Management Co., Ltd. 0.6235 %	3,589,000	0.6235 %	3 M $
Hua Jiang 0.5005 %	2,880,992	0.5005 %	2 M $
Bosera Asset Management Co., Ltd. 0.4637 %	2,669,500	0.4637 %	2 M $
Bank of China Investment Management Co., Ltd. 0.4508 %	2,595,000	0.4508 %	2 M $

CARsgen Therapeutics Holdings Ltd.

CMC Preparation Center No. 388 Yindu Road

200231, Shanghai

http://www.carsgen.com

address CARsgen Therapeutics Holdings Limited(2171)

Sell

Buy

Mean consensus

HOLD

Number of Analysts

Last Close Price

5.045 CNY

Average target price

6.662 CNY

Spread / Average Target

+32.05%

Consensus

Estimates Revisions

Company calendar

Healthcare

Pharmaceuticals & Medical Research

Biotechnology & Medical Research

Biotechnology & Medical Research

Bio Therapeutic Drugs

	1st Jan change	Capi.
CARSGEN THERAPEUTICS HOLDINGS LIMITED	-16.15%	392M
VERTEX PHARMACEUTICALS INCORPORATED	-2.31%	103B
REGENERON PHARMACEUTICALS, INC.	+0.56%	95.71B
ARGENX SE	+1.69%	22.02B
BIONTECH SE	-17.37%	20.9B
GENMAB A/S	-9.30%	17.85B
WUXI APPTEC CO., LTD.	-41.01%	16.21B
BEIGENE, LTD.	-14.85%	15.52B
NEUROCRINE BIOSCIENCES, INC.	+3.21%	13.86B
SAREPTA THERAPEUTICS, INC.	+33.54%	12.04B

Bio Therapeutic Drugs